Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
E-pub ahead of print

Second-line and Third-line therapy for Autoimmune Hepatitis A position statement from the European Reference Network on Hepatological Diseases and the International Autoimmune Hepatitis Group

Research output: Contribution to journalReviewResearchpeer-review

  1. Incidence of Hepatocellular Carcinoma in HIV/HBV-coinfected Patients on Tenofovir therapy: Relevance for Screening Strategies

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Impaired cerebral microcirculation induced by ammonium chloride in rats is due to cortical adenosine release

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Micro-elimination - A path to global elimination of hepatitis C

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. EASL Clinical Practical Guidelines on the management of acute (fulminant) liver failure

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Reply to: "High volume plasma exchange in patients with acute liver failure"

    Research output: Contribution to journalComment/debateResearchpeer-review

  1. Effects of Tumor Necrosis Factor Antagonists in Patients With Primary Sclerosing Cholangitis

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Effects of Vedolizumab in Patients With Primary Sclerosing Cholangitis and Inflammatory Bowel Diseases

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Reversal of Acute Liver Failure Due to Wilson Disease by a Regimen of High-Volume Plasma Exchange and Penicillamine

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Validation of Risk Scoring Systems in Ursodeoxycholic Acid-Treated Patients With Primary Biliary Cholangitis

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Risk markers for later cardiovascular diseases in liver-transplanted children and adolescents

    Research output: Contribution to journalJournal articleResearchpeer-review

  • European Reference Network on Hepatological Diseases (ERN RARE-LIVER) and of the International Autoimmune Hepatitis Group (IAIHG)
View graph of relations

Autoimmune hepatitis in the majority of patients responds well to standard immunosuppressive therapy with steroids and azathioprine, and while untreated disease is usually fatal, patients responding well to therapy have an excellent prognosis. However, about 10-20% of patients present therapeutic challenges due to an insufficient response or intolerable side-effects to standard therapy, requiring dose-adaptation or switch of therapy. While there is a fairly good agreement on second-line treatment options, there is very wide variation in the indication and use of possible third-line therapies. The European Reference Network on Hepatological Diseases (ERN RARE-LIVER) and the International Autoimmune Hepatitis Group (IAIHG) here offer a treatment algorithm for both children and adults that should help to standardize treatment approaches, in order to improve patient care as well as to allow comparison of treatment results in scientific publications.

Original languageEnglish
JournalJournal of Hepatology
ISSN0168-8278
DOIs
Publication statusE-pub ahead of print - 21 Jul 2020

    Research areas

  • 6-Mercaptopurine, Autoimmune hepatitis, Azathioprine, Mycophenolate mofetil

ID: 60546067